Skip to main content
Vivoryon Therapeutics N.V. logo

Vivoryon Therapeutics N.V. — Investor Relations & Filings

Ticker · VVY ISIN · NL00150002Q7 LEI · 3912004AMB0KGZXZYJ15 AS Manufacturing
Open in API
Filings indexed 400 across all filing types
Latest filing 2022-09-30 Capital/Financing Update
Country NL Netherlands
Listing AS VVY

About Vivoryon Therapeutics N.V.

https://www.vivoryon.com/

Vivoryon Therapeutics N.V. is a clinical-stage precision medicine company focused on developing first-in-class therapies by targeting post-translational modifications of proteins. The company's scientific approach centers on inhibiting glutaminyl cyclases (QPCT and QPCTL), enzymes that catalyze pyroglutamate formation, a process implicated in the progression of various diseases. Its lead product candidate, varoglutamstat, is an orally administered small molecule QPCT/L inhibitor. Vivoryon is advancing its therapeutic pipeline for patients with inflammatory, fibrotic, and neurodegenerative diseases, with a strategic focus on conditions such as chronic kidney disease.

Recent filings

Filing Released Lang Actions
Successful Private Placement of up to EUR 30 Million
Capital/Financing Update Classification · 98% confidence The document is a press release dated September 30, 2022, announcing that Vivoryon Therapeutics has entered into a private placement to raise up to EUR 30 Million. The text details the issuance of new ordinary shares, the investors involved (Claus Christiansen and Dawn Biopharma/KKR affiliate), the offering price, and the intended use of proceeds (to support clinical development). This clearly falls under the category of company fundraising and capital structure changes. This aligns directly with the definition for Capital/Financing Update (CAP). Although it mentions a conference call, the primary focus and substance of the document is the financing announcement, not the transcript or the earnings release itself.
2022-09-30 English
Vivoryon Therapeutics N.V.: Vivoryon Therapeutics N.V. Reports H1 2022 Financial Results and Highlights Operational Progress (news with additional features)
Earnings Release Classification · 95% confidence The document is a press release from Vivoryon Therapeutics N.V. announcing its H1 2022 financial results. It contains key highlights, operational progress, and condensed financial statements (Profit or Loss and Financial Position). While it includes financial data, it is structured as an earnings release announcement rather than a full formal interim report document. According to the definitions, an Earnings Release (ER) is the initial announcement of quarterly/periodical financial results containing key highlights. H1 2022
2022-09-30 English
Vivoryon Therapeutics N.V.: Vivoryon Therapeutics Announces Successful Private Placement of up to EUR 30 Million (news with additional features)
Share Issue/Capital Change Classification · 99% confidence The document is an official news release titled "Vivoryon Therapeutics Announces Successful Private Placement of up to EUR 30 Million." It explicitly discusses the issuance of new ordinary shares, the exclusion of pre-emptive rights, the resulting increase in issued share capital, and the intention to use the proceeds for clinical development. Key terms like "Private Placement," "Capital Increase" (as a keyword), and details about share issuance directly relate to financing activities and changes in the capital structure. This aligns perfectly with the definition of a Capital/Financing Update (CAP). Although it mentions a conference call, the primary focus and substance of the release is the capital raise, not the call transcript itself.
2022-09-30 English
to Report H1 2022 Financial Results and Operational Progress on September 30, 2022
Report Publication Announcement Classification · 98% confidence The document is a short press release dated September 26, 2022, announcing that Vivoryon Therapeutics N.V. *will publish* its financial results for H1 2022 on September 30, 2022, and will host a conference call. It explicitly states that the report will be available for download on the website on that future date. According to Rule #2 (The 'MENU VS MEAL' Rule), a document that announces the future publication of a report, rather than containing the full report itself, should be classified as a Report Publication Announcement (RPA). It is not the Interim Report (IR) itself, nor is it a general Earnings Release (ER) which typically contains the actual results summary.
2022-09-26 English
Vivoryon Therapeutics N.V.: Vivoryon Therapeutics N.V. to Report H1 2022 Financial Results and Operational Progress on September 30, 2022
Report Publication Announcement Classification · 99% confidence The document is a news release dated September 26, 2022, announcing that Vivoryon Therapeutics N.V. will publish its financial results for the first six months of 2022 (H1 2022) on September 30, 2022. It provides details for the subsequent conference call and webcast where the results will be discussed. Since the document itself is an announcement about the *future publication* of financial results, and not the comprehensive report (Interim Report/IR) or the initial highlights (Earnings Release/ER), it fits best under the category for announcing the release of reports. This aligns with the definition of Report Publication Announcement (RPA). The document length (6408 chars) is substantial but the core function is announcing the release date and providing access details for the upcoming report and call.
2022-09-26 English
Vivoryon Therapeutics N.V. Presents Preclinical Evidence of Combination Therapy Potential for Varoglutamstat in AD at AAIC 2022
Regulatory Filings Classification · 98% confidence The document text contains detailed updates on clinical trial progress (VIVIAD and VIVA-MIND studies for varoglutamstat), safety data, dose selection decisions by a Data Safety Monitoring Board (DSMB), quotes from management regarding clinical proof of concept, and announcements about upcoming presentations at a conference (AAIC). It also includes forward-looking statements and contact information typical of a corporate news release. This content strongly suggests an announcement intended to inform investors and the public about recent operational and clinical developments, rather than a formal regulatory filing like a 10-K or a comprehensive quarterly report (IR). It is a high-level summary of results and future plans. Given the options, this fits best as an Earnings Release (ER) if it were tied to a financial period, but since it is focused purely on clinical trial milestones and data updates, it is most accurately classified as a general corporate announcement. The presence of the DGAP dissemination notice ('Dissemination of a Corporate News, transmitted by DGAP') points towards a general regulatory/corporate news release. Since there is no specific category for 'Clinical Trial Update' or 'Press Release', the most appropriate fallback category for a significant, non-standard filing that disseminates important corporate news is Regulatory Filings (RNS), which often serves as the catch-all for such announcements not covered by the specific financial report codes.
2022-08-01 English

Browse filings by year

13 years

Report missing filing

Can't find a specific document? Let us know and we'll add it within 24 hours.

We will notify you once the filing is added.
Report sent
Thank you. We will check the data and update it shortly.